Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRON Disc Medicine	$59.38 +2.8%	$51.32	$30.82 ▼ $68.73	$2.00B	0.76	342,088 shs	554,664 shs
SANA Sana Biotechnology	$4.44 -4.1%	$2.78	$1.26 ▼ $7.30	$1.04B	1.86	3.92 million shs	5.19 million shs
SDGR Schrodinger	$22.82 +6.4%	$21.94	$16.60 ▼ $28.47	$1.57B	1.58	927,574 shs	1.64 million shs
TVTX Travere Therapeutics	$15.82 -1.8%	$15.87	$7.93 ▼ $25.29	$1.43B	0.72	1.61 million shs	1.17 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRON Disc Medicine	+2.79%	+2.84%	+15.06%	+34.92%	+30.79%
SANA Sana Biotechnology	-4.10%	+5.21%	+70.11%	+156.65%	-23.45%
SDGR Schrodinger	+6.39%	+7.95%	+11.53%	-12.20%	+6.79%
TVTX Travere Therapeutics	-1.80%	-6.45%	+10.55%	-0.38%	+61.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRON Disc Medicine	3.3666 of 5 stars	4.5	2.0	3.1	2.5	0.0
SANA Sana Biotechnology	3.2453 of 5 stars	3.5	3.0	2.6	3.3	0.6
SDGR Schrodinger	2.062 of 5 stars	3.4	1.0	2.5	1.7	0.6
TVTX Travere Therapeutics	3.5425 of 5 stars	4.4	5.0	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRON Disc Medicine	3.08	Buy	$95.73	61.21% Upside
SANA Sana Biotechnology	3.00	Buy	$9.17	106.46% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	43.51% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	103.18% Upside

Current Analyst Ratings Breakdown

Latest SANA, IRON, TVTX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
7/1/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A
SDGR Schrodinger	$207.54M	8.07	N/A	N/A	$5.78 per share	3.95
TVTX Travere Therapeutics	$233.18M	6.03	N/A	N/A	$0.76 per share	20.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest SANA, IRON, TVTX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IRON Disc Medicine	-$1.17	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	TVTX Travere Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRON Disc Medicine	0.04	37.65	37.65
SANA Sana Biotechnology	N/A	3.40	3.40
SDGR Schrodinger	N/A	3.45	3.45
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRON Disc Medicine	83.70%
SANA Sana Biotechnology	88.23%
SDGR Schrodinger	79.05%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IRON Disc Medicine	4.24%
SANA Sana Biotechnology	31.10%
SDGR Schrodinger	8.60%
TVTX Travere Therapeutics	4.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.20 million	Optionable

SANA, IRON, TVTX, and SDGR Headlines

Recent News About These Companies

Jennison Associates LLC Increases Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 21 at 5:38 AM | marketbeat.com

Brokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $32.14

July 21 at 2:45 AM | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 18, 2025 | marketbeat.com

Research Analysts Set Expectations for TVTX FY2025 Earnings

July 18, 2025 | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Travere Therapeutics

July 17, 2025 | marketbeat.com

Q2 EPS Estimates for Travere Therapeutics Lowered by Wedbush

July 17, 2025 | americanbankingnews.com

Wedbush Expects Lower Earnings for Travere Therapeutics

July 16, 2025 | marketbeat.com

Emerald Advisers LLC Lowers Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 12, 2025 | marketbeat.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025 | businesswire.com

109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | insidermonkey.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | msn.com

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of Stock

July 3, 2025 | insidertrades.com

Q2 EPS Estimate for Travere Therapeutics Cut by Analyst

July 3, 2025 | marketbeat.com

Jula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

July 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

July 2, 2025 | prnewswire.com

1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

July 2, 2025 | benzinga.com

Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

July 1, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Morningstar

June 29, 2025 | morningstar.comM

Travere Therapeutics Inc News (TVTX) - Investing.com

June 27, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

SANA, IRON, TVTX, and SDGR Company Descriptions

Disc Medicine NASDAQ:IRON

$59.38 +1.61 (+2.79%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$59.47 +0.09 (+0.15%)

As of 08:12 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$4.44 -0.19 (-4.10%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$4.48 +0.04 (+0.90%)

As of 08:41 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Schrodinger NASDAQ:SDGR

$22.82 +1.37 (+6.39%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$22.98 +0.16 (+0.68%)

As of 08:42 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Travere Therapeutics NASDAQ:TVTX

$15.82 -0.29 (-1.80%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$15.82 +0.00 (+0.03%)

As of 04:42 AM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time